Avanbulin (BAL27862) is a potent, Colchicine site-binding, tubulin assembly inhibitor. Avanbulin inhibits tubulin assembly at 37 °C with an IC50 of 1.4 μM. Avanbulin binds to tubulin with an apparent Kd value of 244 nM. Avanbulin can be used for the research of cancer and cell division. Avanbulin (0-4 μM) binds to tubulin with an apparent Kd value of 244 nM.Avanbulin (0-20 μM) and Colchicine (0-10 μM) are competitive for binding to tubulin with an apparent Ki value of 1.8 μM.Avanbulin binds to the same site as Colchicine at the intradimer interface.Avanbulin (50 μM; 0, 10, 20, 30, 60 min) induces the proteolysis of tubulin.Avanbulin (1-100 nM; 72 h; HeLa-tubGFP cells) has anti-proliferative effects.Avanbulin (33 nM; 0, 10, 20, 30, 60 min; HeLa-tubGFP cells) collapses the mitotic spindle and forms the tiny tubulin aggregates.Avanbulin does not induce the formation of tubulin oligomers.Avanbulin (0.1 nM-1.0 μM; 96 hours) induces growth inhibition of cells with a median relative IC50 of 13.8 nM.Avanbulin (0-1,000 nM; 3 days) inhibits the growth of glioblastoma cancer stem-like cells, GBM6 (EC50=20.8 nM) and GBM9 (EC50=21.7 nM) .Avanbulin (6 nM and 20 nM) inhibits the migration of GBM6 and GBM9 cells.Avanbulin (6 nM and 20 nM; GBM6-shEB1 and GBM6-sh0 cells) triggers astrocytic differentiation of GBM6 in an EB1-dependent manner.Avanbulin (12 nM; 4 h) reduces kinetochore-microtubule (KT-MT) occupancy of MG132(10 μM; 2h) treated hTert-RPE1 eGFP-α-tubulin cells.Avanbulin (12 nM; 4 h) reduces average inter-KT distances of cells.Avanbulin-treated (12 nM; 4 h) cells show intact spindle morphology and lack of obvious chromosome alignment defects.